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Aims: chronic inﬂammation contributes signiﬁcantly to the morbidity and mortality of chronic hemodialysis patients. A recent
researchhasshownthatadipokineswereassociatedwithinﬂammationinthesepatients.Weaimtoinvestigatewhetherbiomarkers
of inﬂammation, adipokines, and clinical features can predict the outcome of hemodialysis patients. Materials and methods:w e
enrolled181hemodialysispatients(men:97,meanage:56.3±13.6)andanalyzedpredictorsoflong-termoutcomes.Results:during
the 3-year followup period, 41 patients died; the main causes of death were infection and cardiovascular disease. Elevated serum
levels of hsCRPandalbumin andadvanced age were highlyassociated with death(all P<. 001). Leptinand adiponectin levels were
not signiﬁcantly diﬀerent between deceased patients and survivors. Cox-regression analysis indicated that age, diabetes, albumin
level, and hsCRP were independent factors predicting mortality. Conclusion: the presence of underlying disease, advanced age, and
markers of chronic inﬂammation is strongly related to survival rate in long-term hemodialysis patients.
Copyright © 2007 Yu-Che Tsai et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Patients with chronic renal disease have an elevated risk of
cardiovascular disease. For example, a recent study reported
that cardiovascular mortality in dialysis patients is 10 to
20 times higher than the general population [1]. Malnutri-
tion and inﬂammation are often present in patients with
chronic renal disease and are strongly associated with clinical
outcome. Therefore, some researchers have used the terms
“malnutrition-inﬂammation complex syndrome” or “mal-
nutrition, inﬂammation, and atherosclerosis syndrome” to
indicate the interplay of these conditions in dialysis patients
[2, 3]. Among the markers of malnutrition that predict mor-
tality in end stage renal failure (ESRF) patients, serum al-
bumin is more closely associated to comorbidity and age
than nutritional status per se [4]. Proinﬂammatory markers
such as interleukin-6 (IL-6) and tumor necrosis factor alpha
(TNF-α)inducehepaticsynthesisoftheacutephasereactant,
CRP, which is a cardiovascular risk marker and an indepen-
dent risk factor [5]. Recent studies have shown that inﬂam-
mation plays a more important role than hypoalbuminemia
in the pathogenesis of cardiovascular disease [6, 7].
The causes of inﬂammation among dialysis patients are
complex and multifarious. A recent study indicated that fat
tissue secrets numerous adipokines, such as leptin and ado-
ponectinthatcontributetosystemicinﬂammationindialysis
patients[8].Inthe presentstudy,weaimtoexamine whether
demographic data, biomarker of inﬂammation, nutritional
status, and adipokine can predict the outcome of long-term
hemodialysis patients.
2. SUBJECTS AND METHODS
2.1. Subjects
In August 2002, we enrolled a cohort of 181 Taiwanese with
E S R F( 9 7m e na n d8 4w o m e n )w h oh a dr e c e i v e dr e g u l a r
hemodialysis three times a week for at least six months. We
followed the patients for 36 months. The underlying causes
of renal failure were chronic glomerulonephritis (N = 80),
diabetes mellitus (N = 54), hypertension (N = 7), polycystic2 Mediators of Inﬂammation
kidney disease (N = 5), interstitial nephritis (N = 5), sys-
temiclupuserythematous(SLE,N =4),obstructiveuropathy
(N = 1), and unknown etiology (N = 25). All four pa-
tients with SLE were free of disease activity as determined by
clinical judgment and serological markers. None of the pa-
tients suﬀered from acute infection, inﬂammation, or viral
hepatitis at the time of enrollment. Patients with abnormal
liver function results or leucocytosis were excluded from this
study to ensure they were free of infection. All patients re-
ceived hemodialysis 4 hours per session and three sessions
per week. We prospectively followed these patients for 36
months and recorded the survival rate and causes of mor-
tality.
At the initiation of the study, we recorded patient de-
mographics (age, gender, duration of dialysis therapy, and
body mass index, BMI) and the presence of comorbid condi-
tions such as diabetes mellitus and hypertension. The agents
used for blood pressure control were reviewed and recorded
in hypertensives. The duration of hemodialysis is deﬁned
as the number of months from commencement of regular
hemodialysis until enrollment in the present study. We as-
sessed adequacy of dialysis by KT/Vurea and urea reduction
ratio (URR). We used the urea kinetic model of Daugirdas to
determine the KT/Vurea. Normalized protein catabolic rate
(n-PCR, g/kg/day) represents nutritional intake. This study
had been approved by the Institutional Review Boards and
Ethics Committees and all patients were fully informed of
their participation in this study.
2.2. Laboratorymeasurements
We collected fasting blood samples at midweek immediately
prior to the start of hemodialysis via an arterial line and
stored samples at −80◦C. Biochemical data (serum albumin,
total cholesterol, triglyceride, and hemoglobin) and inﬂam-
matory markers (high-sensitivity CRP (hsCRP) interleukin-
6, IL-6, and adipokines (adiponectin and leptin)) were mea-
sured with commercial kits. We used the nephelometry tech-
nique (Behring Diagnostics, Marbury, Germany) to measure
hsCRP, quantitative sandwich enzyme immunoassay tech-
nique (R&D systems, Minneapolis, Minn, USA) to deter-
mine level of IL-6, a human adiponectin RIA kit (Linco Re-
search Lnc., Street Charles, Mo, USA) to measure serum
adiponectin, and a human leptin RIA kit (Linco Research
Lnc., St. Charles, Mo, USA) to measure serum leptin.
2.3. Statisticalanalysis
We performed all statistical analyses using SPSS 13.0 soft-
ware and data were analyzed for normality of distribution
utilizing the Kolmogorov-Smirnov test. Results are expressed
as mean ± SEM for normally distributed data and as me-
dian (interquartile range) for nonparametric data. Student
t-testwasused forcomparison ofmeans between twogroups
and Mann-Whitney U-test for nonparametric data. We fur-
ther determined correlations among all variables with Spear-
man rank test and performed multivariate regression analy-
sis using Cox proportional hazard model to ﬁnd factors most
related to mortality within a 3-year followup. The survival
analysis was conduced by the Kaplan-Meier method based
on serum hsCRP and albumin level, respectively. A P value
<.05 is considered as statistically signiﬁcant.
3. RESULTS
3.1. Demographicandbiochemicaldata
The mean age of the study participants was 56.3 ±13.6y e a r s
and the median duration of dialysis therapy was 44 months
(range 6–188 months). Out of 181 patients, there were 41
deaths during the 36-month followup period. Among de-
ceased patients, 23 patients died of infection (56.1%), 16
of cardiovascular disease (34.1%), and 2 (1.10%) of ter-
minal cancer or accident. Table 1 shows the demographic
data of deceased patients and survivors. Patients who died
during followup were older and more likely to have dia-
betes. There was no signiﬁcant diﬀerence in the duration of
hemodialysis, gender, and BMI between two groups. Ade-
quacy of dialysis, as indicated by KT/Vurea and URR, is sim-
ilar in the two groups. Protein intake, represented as nPCR,
was signiﬁcantly greater in the survivors. Deceased patients
had signiﬁcantly greater levels of serum hsCRP, IL-6, and
lower serum albumin level. There were no signiﬁcant diﬀer-
ences in hemoglobin, total cholesterol, triglycerides, serum
adiponectin, and leptin between the two groups. There was
nodiﬀerenceinadiponectinlevelsbetweenreninangiotensin
inhibitors use and nonuse patients (data not shown).
Lower but not statistically signiﬁcant adiponectin level
was observed in diabetics (median:15.52ug/mL, range: 4.3–
88.03ug/mL) than in nondiabetics (median 21.4ug/mL,
range: 2.43–76.45ug/mL).
3.2. Correlationstudy
Serum hsCRP positively correlated with IL-6 (r = 0.62, P
< .001), BMI (r = 0.304, P < .001), and leptin (r = 0.293,
P < .001) but was negatively correlated with serum albu-
min (r = −0.486, P < .001) and adiponectin (r = −0.225,
P < .001). No association between CRP and nPCR was found
(r = −0.092, P = .225). IL-6 positively correlated with leptin
(r = 0.232, P < .005) and BMI (r = 0.287, P < .01) but not
withadiponectin(r = −0.115,P =.255)ornPCR(r = −0.043,
P = .672). There was a negative correlation between leptin
and adiponectin levels (r = −0.191, P < .05). Serum albu-
min correlated positively with nPCR (r = 0.261, P < .001)
and negatively with serum hsCRP and IL-6 (r = −0.414,
P < .001) but had no signiﬁcant relationship with leptin
(r = −0.137, P = .084), adiponectin (r = 0.024, P = .753),
or BMI (r = −0.010, P = .181). The BMI positively correlated
with serum hsCRP and leptin (r = 0.404, P < .001) and neg-
atively with serum adiponectin (r = −0.287, P < .001).
3.3. Cox-regressionanalysis
We used the signiﬁcant correlation coeﬃcients in a Cox-
regression analysis (Table 2). The results show that advanced
age, serum hsCRP level, albumin level, and presence ofYu-Che Tsai et al. 3
Table 1: Comparison between survivors and deceased patients in our population of long-term hemodialysis patients. Data are the number
of patients or the mean ± SEM for normally distributed data and median (interquartile range) for nonparametric data; BMI: body mass
index; URR: urea reduction rate; nPCR: normalized protein catabolism rate.
Death (n = 41) Survival (n = 140) P value
Age (years) 64.3 ±11.65 3 .9 ±13.2 <0.001
Gender (male) 24 73 0.470
Diabetes mellitus 22 104 0.012
Hypertension 28 97 0.904
Duration on dialysis (months) 46.0 (19−90) 44.0 (19−76.5) 0.803
BMI (kg/m2)2 3 .1 ±4.32 2 .9 ±3.4 0.803
URR (%) 0.75 ±0.07 0.74 ±0.06 0.217
Kt/V 1.44 ±0.28 1.37 ±0.24 0.172
nPCR (g/kg/day) 1.09 ±0.30 1.21 ±0.24 0.032
Hs-CRP (mg/L) 7.07 (2.59−13.24) 2.28 (0.98−7.84) <0.001
IL-6 (pg/mL) 6.27 (2.67−12.39) 2.83 (0.2−7.78) 0.039
Serum albumin (g/dL) 3.42 ±0.36 3.72 ±0.33 <0.001
Leptin (ng/mL) 14.8 (7.43−38.08) 15.2 (6.48−33.85) 0.492
Adiponectin (ug/mL) 20.78 (10.45−34.0) 20.48 (13.48−30.37) 0.751
Hemoglobulin (g/dL) 9.6 (8.7−10.7) 9.8 (8.8−10.8) 0.922
Total cholesterol (mg/dL) 175.0 ±43.4 191.5 ±44.5 0.077
Triglyceride (mg/dL) 136.0 (96−262.5) 161.5 (106.80−229.8) 0.786
Table 2: Cox-regression analysis for independent predictors of
mortality in hemodialysis patients.
Wald Relative risk Pv a l u e
Hs-CRP 11.731 1.046 0.001
Diabetes mellitus 4.868 0.467 0.027
Age 5.024 1.038 0.025
Albumin 5.565 0.274 0.018
diabetes mellitus are independent predictors for mortality in
chronic hemodialysis patients.
3.4. Survivalanalysis
The Kaplan-Meier survival curve, determined from baseline
hsCRP level (Figure 1), demonstrated that patients within
thehighestquartile(hsCRP>8.8mg/L)hadthehighestmor-
tality (3-year survival rate: 64.4%) in comparison with the
other three quartiles (hsCRP < 1.23mg/L: 93.6%, hsCRP
1.23 to 3.0mg/L: 79.1%, hsCRP 3.1 to 8.8mg/L: 71.7%, all P
< .05). There was no signiﬁcant diﬀerence between the other
three quartiles. Baseline albumin level predicts survival rate
and patients in the lowest group (albumin < 3.5g/dL) had
the lowest survival rate (63.2%) compared with the other
three quartiles (albumin 3.5 to 3.7g/dL: 81.4%, albumin 3.8
to 4.0g/dL: 89.7%, albumin > 4.0g/dL: 95.5%, all P < .05).
The survival rate was similar between the other three quar-
tiles.
4. DISCUSSION
Ourresultsclearlydemonstratethatpatients withmoresigns
of inﬂammation and lower albumin levels face an increased
0.6
0.7
0.8
0.9
1
C
u
m
u
l
a
t
i
v
e
s
u
r
v
i
v
a
l
01 0 2 03 0 4 0
Time (months)
Quartile 1 <= 1.23mg/L
Quartile 2 1.23 ∼ 3mg/L
Quartile 3 3 ∼ 8.8mg/L
Quartile 4 >= 8.8mg/L
Figure 1: Kaplan-Meier survival curve for all-cause mortality in
hemodialysis patients. We classiﬁed patients into four quartiles
based on serum hsCRP levels.
risk of all-cause mortality. Furthermore, comparison be-
tween survivors and deceased patients found that deceased
patients were older and more likely to have diabetes. It has
been long recognized that diabetes is an independent predic-
tor of mortality in dialysis patients [9, 10]. However, in con-
trast to previous studies, we found that hypertension did not
contribute to mortality. It is possible that control of blood
pressure in our patients may have reduced the impact of
blood pressure on overall mortality.4 Mediators of Inﬂammation
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Figure 2: Kaplan-Meier survival curve for all-cause mortality in
hemodialysis patients. We classiﬁed patients into four quartiles
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Previous studies have shown that CRP, a product of the
inﬂammatory response, contributes to atherosclerosis, car-
diovascular risk, and mortality in dialysis patients [11, 12].
Our study shows, as expected, that hsCPR level correlated
withBMIandIL-6levels,butinverselycorrelatedwithserum
albumin and adiponectin. Moreover, hsCRP is an indepen-
dent factor associated with risk of mortality in the present
study. This result illustrates the critical importance of in-
ﬂammation in dialysis population. As an upstream pro-
inﬂammation marker, IL-6 promotes expression of CRP
gene in the liver, and elevated level is a strong predictor of
atherosclerosis and mortality in dialysis patients [13]. Al-
though IL-6 level was lower in the survivals, our study did
not support its predicting role.
The prevalence of malnutrition is as high as 34% to 60%
in ESRD patients, and the impact of malnutrition on patient
outcome has been investigated [14] .H o w e v e r ,as i n g l em e a -
surement of serum albumin is more closely related to mor-
tality and inﬂammation than nutritional status in patients
near the start of dialysis therapy [4]. Furthermore, hypoal-
buminemia is not only presented as malnutrition, it is also
the most analytical factor of graft thrombosis, arthrosclero-
sis, and can predict all causes and cardiovascular mortality in
dialysis patients [15]. Our results show that albumin level in-
dependently predicts mortality, representing its unique role
that is not necessarily related to inﬂammation. Among dial-
ysis patients, many factors other than inﬂammation can in-
ﬂuence serum albumin levels [16]. Thus, the relationship be-
tween inﬂammation and malnutrition is complex. Though
serum albumin level was related with protein intake, lack of
association between nPCR and inﬂammatory markers sug-
gests that albumin level per se is not solely a marker of nutri-
tional status in dialysis patients.
Adipose tissue stores energy and also secretes inﬂamma-
tory cytokines (leptin, adiponectin, resistin, IL-6, and tumor
necrotic factor alpha) that contribute to systemic inﬂamma-
tion. Zoccali et al. [17] performed a longitudinal study in
chronic renal failure patients and found that leptin was up-
regulated when an infection triggered acute inﬂammation.
They considered this adipokine as an inverse acute-phase re-
actant. With the positive correlation of leptin with hsCRP
and IL-6, our study supports this conclusion. Previous stud-
ies have shown that plasma adiponectin level is a negative
predictor of cardiovascular outcomes among patients with
ESRF[18],andhasinverserelationshipwithleptinlevel[19].
Recent evidence suggests that adiponectin might have an an-
tiatherogenic property and serve as a protective molecule.
In our previous study, serum leptin and adiponectin lev-
els were elevated in hemodialysis patients, and they corre-
lated signiﬁcantly with inﬂammation markers [20]. In the
present longitudinal observation, however, we did not ﬁnd
that adipokines were associated with mortality. Some previ-
ous studies found that adiponectin was an independent pre-
dictor of all-cause mortality [21, 22], but other studies have
not conﬁrmed these results [23, 24]. It is unknown whether
the protective eﬀect of adiponectin was masked by the in-
creased cardiovascular risk among dialysis patients. Further
studies are needed to clarify the role of adipokine in dialy-
sis patients. Therapeutic interventions that modulate the ef-
fect(s) of adipokines should be able to directly test this hy-
pothesis.
Traditional risk factors such as total cholesterol and
triglyceride levels examined in this study did not demon-
strate the association with inﬂammation as well as mortality.
This result is similar to previous studies [6, 15]b u td o e sn o t
exclude the importance of dyslipidemia in dialysis patients
at all. For renal anemia, successful treatment with erythro-
poietin therapy can save patients from anemia-related mor-
bidityandmortality.Inthestudyofdialysispatientoutcome,
therearestillsomemodiﬁableandnonmodiﬁablefactorsnot
included in our analysis. Therefore, we can not address any
conclusiononthesefactorswithregardsonmortality.Onthe
other hand, small patient size and short followup period are
another study limitation. More participants can allow us to
examine study endpoints such as comorbidity and diﬀerent
cause of mortality.
5. CONCLUSIONS
Chronic inﬂammation is prevalent among dialysis patients
whohaveelevatedplasmaadipokines.Chronicinﬂammation
and hypoalbuminemia, but not elevated adipokines, are re-
lated to all-cause mortality. This suggests an important role
of chronic inﬂammation and hypoalbuminemia for the out-
come of long-term hemodialysis patients.
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